You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
COMPASS Pathways plc expects to file its final NDA in the next two weeks and remains on track for an H12027 launch, subject to FDA approval. Cash and cash equivalents were $444.0 million as of September 30, 2026.
COMPASS Pathways said COMP360 met primary endpoints in Phase 3 COMP005 and COMP006 for TRD; the FDA granted rolling NDA review and a National Priority Voucher. It had $444.0 million cash and expects funding into 2028.
